Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Meiji to Launch Japan PIb/II of Hiyasta for B-cell Non-Hodgkin’s Lymphoma
Meiji Seika Pharma said on December 22 that it will initiate a PIb/II clinical trial in Japan to obtain an additional indication for the anti-malignant tumor agent Hiyasta (tucidinostat). The trial is expected to begin next March. The trial will…
To read the full story
Related Article
- HUYA’s Hiyasta Enters PIII Melanoma Study in Japan: Meiji
April 26, 2023
- HUYA Japan to Transfer Hiyasta Marketing Authorization to Meiji
December 1, 2022
BUSINESS
- Novartis Japan Chief Urges Pro-Innovation Policies to Sustain Investments
April 21, 2026
- Nxera Bags US$10 Million Milestone from AbbVie in Neuro Collaboration
April 21, 2026
- Asahi Kasei Closes Aicuris Buy, Eyes US$500 Million Sales by 2030
April 21, 2026
- 3D Slams Toho’s Info Requests as Bid to Justify Defense Measures
April 21, 2026
- Mitsui Fudosan, LINK-J, SS-F Launch Rental Lab Hub in Yokohama
April 21, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…